DiaMedica Therapeutics Says Trial of DM199 to Treat Acute Ischemic Stroke Reaches 75% Enrollment

MT Newswires Live

05/20

DiaMedica Therapeutics (DMAC) said Wednesday that enrollment of its phase 2/3 trial of DM199 to treat patients with acute ischemic stroke has reached 75% of its target of 1,200 patients.

The biopharmaceutical company said if it reaches 100% enrollment, it will trigger a planned interim analysis. The company also said it still expects the interim analysis to be completed by the end of 2026.

The interim analysis will be conducted by the independent Data Safety Monitoring Board to determine if a sample size re-estimation is recommended for the trial.

Shares of DiaMedica rose more than 2% pre-bell Wednesday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2636836840"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2636836840\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2636836840?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-20 21:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2636836840","market":"nz","top_or_hot":-1,"title":"DiaMedica Therapeutics Says Trial of DM199 to Treat Acute Ischemic Stroke Reaches 75% Enrollment","media":"MT Newswires Live","content":"<html><body><p> DiaMedica <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (DMAC) said Wednesday that enrollment of its phase 2/3 trial of DM199 to treat patients with acute ischemic stroke has reached 75% of its target of 1,200 patients.</p><p>The biopharmaceutical company said if it reaches 100% enrollment, it will trigger a planned interim analysis. The company also said it still expects the interim analysis to be completed by the end of 2026.</p><p>The interim analysis will be conducted by the independent Data Safety Monitoring Board to determine if a sample size re-estimation is recommended for the trial.</p><p>Shares of DiaMedica rose more than 2% pre-bell Wednesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DiaMedica Therapeutics Says Trial of DM199 to Treat Acute Ischemic Stroke Reaches 75% Enrollment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDiaMedica Therapeutics Says Trial of DM199 to Treat Acute Ischemic Stroke Reaches 75% Enrollment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-20 21:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> DiaMedica <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (DMAC) said Wednesday that enrollment of its phase 2/3 trial of DM199 to treat patients with acute ischemic stroke has reached 75% of its target of 1,200 patients.</p><p>The biopharmaceutical company said if it reaches 100% enrollment, it will trigger a planned interim analysis. The company also said it still expects the interim analysis to be completed by the end of 2026.</p><p>The interim analysis will be conducted by the independent Data Safety Monitoring Board to determine if a sample size re-estimation is recommended for the trial.</p><p>Shares of DiaMedica rose more than 2% pre-bell Wednesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2636836840","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2636836840","pubTimestamp":1779282310,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"DiaMedica Therapeutics  said Wednesday that enrollment of its phase 2/3 trial of DM199 to treat patients with acute ischemic stroke has reached 75% of its target of 1,200 patients.The biopharmaceutical company said if it reaches 100% enrollment, it will trigger a planned interim analysis. The company also said it still expects the interim analysis to be completed by the end of 2026.The interim analysis will be conducted by the independent Data Safety Monitoring Board to determine if a sample size re-estimation is recommended for the trial.Shares of DiaMedica rose more than 2% pre-bell Wednesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","DMAC":"DiaMedica Therapeutics Inc.","BK4139":"生物科技","LENZ":"Therapeutics","BK4007":"制药"},"translate_title":"DiaMedica Therapeutics表示DM199治疗急性缺血性中风的试验入组率达到75%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DMAC":1,"LENZ":1.5},"content_text":"DiaMedica Therapeutics (DMAC) said Wednesday that enrollment of its phase 2/3 trial of DM199 to treat patients with acute ischemic stroke has reached 75% of its target of 1,200 patients.The biopharmaceutical company said if it reaches 100% enrollment, it will trigger a planned interim analysis. The company also said it still expects the interim analysis to be completed by the end of 2026.The interim analysis will be conducted by the independent Data Safety Monitoring Board to determine if a sample size re-estimation is recommended for the trial.Shares of DiaMedica rose more than 2% pre-bell Wednesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}